Anti-C170 [NCRC22]
Invented by Prof Lindy Durrant from University of Nottingham
Invented at University of Nottingham
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 152937 |
| Applications | ELISA FACS |
| Antigen/Gene or Protein Targets | C170 - Colorectal carcinoma cell line |
| Reactivity | Human |
| Relevance | Colorectal carcinoma is one of the most common malignant neoplasms. The cell line C170 was derived directly from a human primary tumor and as such was used as an immunogen to generate an antibody which is able to detect an epitope of a variety of colorectal cancerous cell lines. |
| Host | Mouse |
| Immunogen | C170 cells |
| Positive Control | Cell lines: C168, MKN45, HT29, A549, Colo205 |
| Subclass | IgG1 |
| Myeloma Used | P3NSI-Ag-1 |
| Strain | Balb/c |
| Notes | Also binds to: granulocytes |
| Research Area | Cancer, Cell Type or Organelle Marker, Epitope Tags |
References: 2 entries
Durrant et al. 1986. Br J Cancer. 53(1):37-45. PMID: 3947514.
Antigenicity of newly established colorectal carcinoma cell lines.
Europe PMC ID: 3947514
Add a reference
References: 2 entries
Durrant et al. 1986. Br J Cancer. 53(1):37-45. PMID: 3947514.
Antigenicity of newly established colorectal carcinoma cell lines.
Add a reference
